The company's major products are Prolia and XGEVA (Denosumab) for treatment ofosteoporosis and bone diseases ($6.7 billion in total 2024 revenues), Enbrel (Etanercept) for treatment of autoimmune diseases ($3.3 billion in 2024 revenues), Repatha (evolocumab) for treatment ofhyperlipidemia ($2.3 billion in 2024 revenues), Otezla (apremilast) for treatment ofpsoriasis andpsoriatic arthritis ($2.1 billion in 2024 revenues), Tepezza (teprotumumab) to treatGraves' ophthalmopathy ($1.8 billion in 2024 revenues), Evenity (romosozumab) to treatosteoporosis ($1.5 billion in 2024 revenues), Kyprolis (carfilzomib) to treat cancer ($1.5 billion in 2024 revenues), Nplate (romiplostim) to regulate platelet production ($1.4 billion in 2024 revenues), and Aranesp (darbepoetin alfa) to stimulateerythropoiesis ($1.3 billion in 2024 revenues).[1]
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, ananti-obesity medication administered once per month by injection.[2]
AMGen corporate logo, 1983Argentine presidentMauricio Macri meets with heads of Amgen, in 2018.
In April 1980, Amgen was founded in Thousand Oaks as Applied Molecular Genetics.[5] Amgen was backed by a small group of venture capitalists, and its early focus was onrecombinant DNA technology and recombinant humaninsulin.[6]
In June 1984, Amgen and Kirin formed a joint venture giving Kirin the rights to Epogen in Japan.[14][15] A year later, Amgen researcher Larry Souza and his team clonedgranulocyte colony-stimulating factor (G-CSF), leading to the development of Neupogen (filgrastim).[13][16][17]
In October 1988,Gordon Binder was named CEO, succeeding George Rathmann.[18] The following year, in 1989, Amgen received approval for the first recombinant human erythropoetin product, Epogen (epoetin alfa).[19]
In February 1991, Amgen received FDA approval for Neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy.[20]
Amgen opened a new manufacturing facility inPuerto Rico, in March 1993, which later became the company's flagship manufacturing site.[21]
In 1994, Amgen became the fifth company to receive theNational Medal of Technology and Innovation from theUnited States Department of Commerce, in recognition of its work developing medicines to improve quality of life for kidney and cancer patients.[22] Also around this time, Amgen researcher Steve Elliott and his team added more sugar molecules to erythropoietin, causing it to remain in the body longer. This led to the development of Aranesp (darbepoetin alfa).[23]
Binder was succeeded as CEO byKevin W. Sharer in 2000.[24] Robert A. Bradway became Amgen's president and chief executive officer in May 2012, following Sharer's retirement.[25]
In June 2010, Amgen received approval by theFood and Drug Administration for Prolia, a protein drug for the treatment of post-menopausal osteoporosis.[26] In clinical trials, Prolia reduced the rate of vertebral fractures by 61% and the risk of hip fractures by 40%.[27] In November 2010, theFDA approved Xgeva for the prevention of complications of bone metastases in patients with solid tumors.[28] The clinical trials primarily enrolled patients with breast or prostate cancer.
In March 2011, Amgen acquired a manufacturing facility near Dublin, Ireland.[29]
Amgen opened an affiliate in China in 2013.[30][31]
In November 2014, the company halted all trials ofrilotumumab in advancedgastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy, than those without.[32] Also in November 2014, the company, in conjunction withAstraZeneca, reported positive results forbrodalumab in a Phase III trial comparing the compound withustekinumab and aplacebo in treatingpsoriasis.[33] In the same month, construction was completed on Amgen's next-generation biomanufacturing facility in Singapore.[34] Blincyto (blinatumomab) was approved by the FDA in December of that year.[35][36]
In March 2015, the company announced that it would license its Phase II candidate drug AMG 714 to Celimmune, which will develop the anti-IL-15monoclonal antibody for treatment against diet nonresponsiveceliac disease and refractory celiac disease.[37] In August 2015, Repatha (evolocumab) was approved by the FDA.[38]
In September 2016, the company announced it would purchase the rights toBoehringer Ingelheims Phase I bispecific T-cell engager compound (BI 836909, now AMG 420) for use in the treatment ofmultiple myeloma.[39] Also in September, the FDA approved Amjevita (adalimumab-atto).[40] The FDA approved Parsabiv in February 2017[41] and Mvasi (bevacizumab-awwb) in September.[42]
In January 2019, Evenity (romosozumab) received approval in Japan,[45][46] followed by FDA approval in April.[47] In June, Kanjinti (trastuzumab-anns) was approved by the FDA.[48]
In December 2019, the FDA approved Avsola (infliximab-axxq).[49]
In August 2020, Amgen,Takeda Pharmaceutical Company, andAbbVie, as part of a COVID-19 research and development (R&D) alliance, announced the first patients enrolled in the I-SPY COVID clinical trial. The trial evaluated the efficacy of Otezla and two other medicines in severely ill, hospitalized COVID-19 patients who required high-flow oxygen.[54]
In September 2020, Amgen andEli Lilly and Company announced a global manufacturing collaboration forCOVID-19 antibody therapies.[55]
In October 2020, Amgen announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib in 126 patients with KRAS G12C-mutant advanced NSCLC who had failed three or fewer prior lines of anti-cancer therapies (includingimmunotherapy and/or chemotherapy).[56] Amgen, the Global Coalition for Adaptive Research, andEisai Co., Ltd. also announced enrollment of the first patient in a study testing multiple interventions for the treatment of patients hospitalized with COVID-19.[57]
In November 2020, Amgen, Takeda, andUCB, as part of the COVID R&D alliance, announced the first patient enrolled in another trial evaluating Otezla and two other drugs as treatments for COVID-19.[58] Amgen also announced that it would terminate its collaboration withCytokinetics and transition the development and commercialization rights foromecamtiv mecarbil and AMG 594.[59] Amgen andAstraZeneca announced positive topline results from a Phase 3 trial in which the investigational medicinetezepelumab demonstrated a statistically significant reduction in exacerbations in patients with severe asthma.[60]
In December 2020, the FDA grantedbreakthrough therapy designation to sotorasib for advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation.[61] Also in December 2020, the FDA approved Riabni (rituximab-arrx), a biosimilar to Rituxan.[62][63]
In April 2021, the company acquired Five Prime Therapeutics and its lead candidate,bemarituzumab, for $1.9 billion.[64][65][66][67]
In the March 2021, Amgen acquired Rodeo Therapeutics for $720 million.[68][69]
In May 2021, sotorasib received accelerated approval from FDA for treatment of adult patients with NSCLC whose tumors have a KRAS G12C mutation and who have received at least one prior systemic therapy; this was the first approved targeted therapy for tumors with any KRAS mutation.[70] Similar approvals for sotorasib in NSCLC followed in January 2022 in Europe[71] and Japan.[72] The FDA approved Amgen'sLumakras in May for treatment of patients with KRAS-G12C-mutated non-small cell lung cancer.[73]
In June 2021, Amgen andKyowa Kirin announced joint plans to develop and commercialize a treatment foratopic dermatitis.[74] In October, Amgen and Neumora Therapeutics announced a research and development collaboration focused on novel precision therapies for certain brain diseases.[75][76] Amgen began construction on a new biomanufacturing plant inNew Albany, Ohio, in November.[77] In December, the FDA approved Amgen and AstraZeneca's Tezspire (tezepelumab) for severeasthma.[78] The FDA also approved Amgen's Otezla for adults with plaquepsoriasis of any severity level.[79]
Amgen announced a research collaboration in January 2022 with Generate Biomedicines across multiple modalities and several therapeutic areas for up to $1.9 billion.[80][81] The company also launched a multi-target collaboration withArrakis Therapeutics to identify novel targeted RNA degrader therapeutics.[82][83] The next month, Amgen entered a multi-year collaboration with Plexium to discover novel targeted protein degradation therapies.[84][85] Also in February, Amgen issued its firstgreen bond to fund various environmentally friendly initiatives across the company.[86][87] The company broke ground on a new manufacturing facility inHolly Springs, North Carolina, in March.[88][89]
In September 2022, data from a late-stage study showed the company's cancer pill Lumakras (sotorasib) beating outchemotherapy. This was the first approved drug in the set of treatments that target KRAS, among the most common generic mutations found in cancers. The drug was approved in 2021 with a list price of $17,900 per month.[90]
In October 2022, the company acquired ChemoCentryx, the maker ofTavneos—a drug treatment for rare diseases called anti-neutrophil cytoplasmic autoantibody-associatedvasculitis, for $3.7 billion in an all-cash deal.[91][92][93]
In October 2023, Amgen acquiredHorizon Therapeutics, specializing in drugs for rare diseases, for $27.8 billion.[94][95]
Also in March 2025, Amgen announced the start of two late-stage trials for MariTide, ananti-obesity medication candidate.[98][99] In June 2025, the company noted that it had to reduce the dosage of the drug to avoid side effects such as vomiting.[100] However, patients that continued to take the drug lost approximately 20% of their body weight.[101]
In April 2025, the company announced a $900 million expansion of its facility inNew Albany, Ohio.[102] In September 2025, it announced plans to build a $600 million research center inThousand Oaks, California.[103]
In October 2017, the Amgen Foundation pledged $3 million toKhan Academy to support the development of free online biology lessons.[116][117] In July 2020, Amgen granted an additional $3 million Khan Academy to support educational equity and science learning.[118][119]
In January 2020, the Amgen Foundation andHarvard University debuted LabXchange, a free online science education platform.[120][121] Amgen and the Amgen Foundation announced a commitment of up to $12.5 million to support COVID-19 relief efforts in March.[122]
In November 2021, Amgen awarded a $2 million grant to theCDC Foundation to launch the latter's EmPOWERED Health Program, promoting patient engagement in decision making for cancer treatments.[123]
The company spends approximately $10 million per year onlobbying in the United States. Political contributions have mostly been to individuals and organizations associated with theDemocratic Party.[124]
Imlygic (talimogene laherparepvec) for local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in melanoma recurrent after initial surgery (FDA approved October 2015)[128]
Xgeva (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone in adults with bone metastases from solid tumors)
In December 2012, Amgen plead guilty and agreed to pay $150 million in criminal penalty and $612 million to resolve 11 relatedwhistleblower complaint related to improper marketing ofanemia drugAranesp. According to theUnited States Department of Justice, Amgen sold the drug foroff-label uses at dosages that the FDA had rejected or never approved.[137][138]
In May 2025, a jury ruled that Amgen owesRegeneron $406 million for engaging in anticompetitive practices to increase sales of its cholesterol-reduction drug Repatha at the expense of Regeneron's Praluent.[139]
US$33.4 billion (2024)
US$7.26 billion (2024)
